Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: Selective actions relative to 3,5,3′-triiodo-L-thyronine

Endocrinology

Volumn 145, Issue 4, 2004, Pages 1656-1661

  Grover, Gary J ^a   Egan, Donald M ^a   Sleph, Paul G ^a   Beehler, Blake C ^a   Chiellini, Grazia ^c   Nguyen, Ngoc Ha ^b   Baxter, John D ^b   Scanlan, Thomas S ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GC 1; LIOTHYRONINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; BODY WEIGHT; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEART RATE; HYPERLIPIDEMIA; MALE; METABOLIC RATE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; TACHYCARDIA;

ACETIC ACIDS; ANIMALS; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, DIETARY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; LIPOPROTEIN(A); MACACA FASCICULARIS; MALE; PHENOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THYROID HORMONE; TRIIODOTHYRONINE;

EID: 1642505721     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0973     Document Type: Article

References (28)

1. Yen PM 2001 Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-1142
2. Lazar MA 1993 Nuclear hormone receptor: multiple forms, multiple possibilities. Endocr Rev 14:348-399
3. Davignon J 1995 Prospects for drug therapy for hyperliproteineamia. Diabetes Metab 21:139-146
4. Forrest D, Vennström B 2000 Functions of thyroid hormone receptors in mice. Thyroid 10:41-51
5. 1. EMBO J 17:455-461
6. Schwartz HL, Strait KA, Ling NC, Oppenheimer JH 1992 Quantitation of rat tissue thyroid hormone binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. J Biol Chem 267:11794-11799
7. Johansson C, Vennström B, Thoren P 1998 Evidence that decreased heart rate inthyroid hormone receptor α1-deficient mice is an intrinsic defect. Am J Physiol 275:R640-R646
8. Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan T, Dillmann WH 2000 The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141:3057-3056
9. Weiss RE, Murata Y, Cua K, Hayashi AY, Seo H, Refetoff S 1998 Thyroid hormone action on liver, heart and energy expenditure in thyroid hormone receptor β deficient mice. Endocrinology 139:4945-4952
10. Grover GJ, Mellstrom K, Ye L, Malm J, Li Y, Bladh L-G, Sleph PG, Smith MA, George R, Vennstrom B, Mookhtiar K, Horvath R, Speelman J, Baxter JD 2003 Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, chlosterol, and Lp(a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 100:10067-10072
11. Iossa S, Liverini G, Barletta A 1992 Relationship between the resting metabolic rate and hepatic metabolism in rats: effect of hyperthyroidism and fasting for 24 hours. J Endocrinol 135:45-51
12. Oppenheimer JH, Schwartz HL, Lane JT, Thompson, MP 1991 Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J Clin Invest 87:125-132
13. Chiellini G, Apriletti, JW, Yoshihara HA, Baxter J, Ribeiro RJ, Scanlan TS 1998 A high affinity subtype-selective agonist ligand for thyroid hormone receptor. Chem Biol 5:299-306
14. Steele RE 1995 CGS-23425, the thyroxine connection revisited. In: Woodford FP, Davignon J, Sniderman, A, eds. Atherosclerosis X. New York: Elsevier Science B. V.; 321-324
15. Rakow AD, Klor HU, Kuter E, Ditschuneit HH, Kitscheneit H 1976 Treatment of type II hyperlipoproteinemia with d-thyroxine. Atherosclerosis 24:369-380
16. Scarabottolo L, Trezzi E, Roma P, Catapan L 1986 Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. Atherosclerosis 59:329-333
17. Ridgway D, Dolphin PJ 1985 Serum activity and hepatic secretion of lecithin cholesterol acyltransferase in experimental hypothyroidism and hypercholesterolemia. J Lipid Res 26:1300-1313
18. Engler H, Riesen WF 1993 Effect of thyroid function on concentrations of lipoprotein (a). Clin Chem 39:2466-2469
19. de Bruin TW, van Barlingen H, van Linde-Sibenius Trip M, van Vuurst de Vries AR, Akveld MJ, Erkelens DW 1993 Lipiporotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthryoid, and hyperthyroid subjects. J Clin Endocrinol Metab 76:121-126
20. Klein I, Ojamaa K 2001 Thyroid hormone and the cardiovascular system. N Engl J Med 344:501-509
21. Underwood H, Emmett JC, Ellis D, Flynn SB, Leeson P, Benson GM, Novelli R, Pearce NJ, Shah VP 1986 A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 324:425-429
22. Stephan ZF, Yurachek E, Sharif R, Wasvary JM, Leonards KS, Hu C, Hintze TH, Steele RE 1996 Demonstration of potent lipid-lowering activity by a thyromimetic agent devoid of cardiovascular and thermogenic effects. Atherosclerosis 126:53-63
23. Barlow JW, Raggatt LE, Lim C, Kolliniatis E, Topliss DJ, Stockigt JR 1991 The thyroid hormone analogue SKF-94901 and iodothyronine binding sites in mammalian tissues: differences in cytoplasmic binding between liver and heart. Acta Endocrinol 124:37-44
24. Gloss B, Trost S, Bluhm W, Swanson E, Clark R, Winkfein R, Janzen K, Giles W, Chassande O, Samarut J, Dillmann W 2001 Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor α or β. Endocrinology 142:544-551
25. Ye L, Mellstrom K, Bladh L, Koehler K, Garg N, Collazo A, Litten C, Husman B, Persson K, Ljunggren J, Grover G, Sleph, George R, Malm J 2003 Agonist ligands selective for the thyroid receptor β. J Med Chem 46:1580-1588
26. Gelfand RA, Hutchinson-Williams KA, Bonde AA, Castellino P, Sherwin RS 1987 Catabolic effects of thyroid hormone excess: the contribution of adrenergic activity to hypermetabolism and protein breakdown. Metabolism 36: 562-569
27. Kordik CP, Reitz AB 1999 Pharmacological treatment of obesity: therapeutic strategies. J Med Chem 42:182-201
28. Pedersen TR, Tobert JA 1996 Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 14:11-24